CATHERINE LE M.D.
Prescription History 1457794364
Internal Medicine - Infectious Disease in Nashville, TN


Quality Rating: 85.71 out of 100 score

NPI Status: Active since April 10, 2013

Contact Information

1211 MEDICAL CENTER DR
NASHVILLE, TN
ZIP 37232
Phone: (615) 322-5000

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for CATHERINE LE M.D., an active Infectious Disease specialist practicing in Nashville, TN. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 133 documented patient claims. Among these therapy options, the most frequently utilized medication is Imipenem-Cilastatin Sodium, which accounts for 51 claims alone.

Medication Index

No matching medications currently found on file.

Amikacin Sulfate

Generic Formulation: Amikacin SulfateSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 34
30-Day Fills 34.0
Days Supply 231
TN State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills32.0
Peer Average Days Supply363
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,372.63 across this reporting matrix range.

Provider Avg Cost Per Claim

$69.78

State Avg Cost Per Claim

$82.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.

Therapeutic Applications

This medication is used to prevent or treat a wide variety of bacterial infections. Amikacin belongs to a class of drugs known as aminoglycoside antibiotics. It works by stopping the growth of bacteria.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 27.8
Days Supply 810
TN State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills43.0
Peer Average Days Supply302
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 73.2% less volume than the regional standard for practitioners inside TN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $504.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$45.85

State Avg Cost Per Claim

$9.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Biktarvy

Generic Formulation: Bictegrav/Emtricit/Tenofov AlaSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 570
TN State Average Benchmarks
Peer Average Claims88.0
Peer Average 30-Day Fills90.0
Peer Average Days Supply2,700
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 78.4% less volume than the regional standard for practitioners inside TN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $74,907.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,942.51

State Avg Cost Per Claim

$3,929.95

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination product is used by itself to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of 3 different drugs: bictegravir, emtricitabine, and tenofovir alafenamide. Bictegravir is called an integrase strand transfer inhibitor-INSTI. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. Emtricitabine and tenofovir alafenamide are often called NRTIs. Bictegravir/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Ceftriaxone

Generic Formulation: Ceftriaxone SodiumSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 119
TN State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills30.2
Peer Average Days Supply135
Conservative Utilization

This provider writes prescriptions for this formulation 40.0% less frequently than the standard regional baseline metric for practitioners inside TN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,105.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$339.22

State Avg Cost Per Claim

$61.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.

Therapeutic Applications

Ceftriaxone is used to treat a wide variety of bacterial infections. This medication belongs to a class of drugs known as cephalosporin antibiotics. It works by stopping the growth of bacteria. This drug is not recommended for use in newborns with high blood bilirubin levels and premature infants due to increased risk of side effects. Ask the doctor or pharmacist for details.

Imipenem-Cilastatin Sodium

Generic Formulation: Imipenem/Cilastatin SodiumSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 51
30-Day Fills 51.0
Days Supply 151
TN State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills19.5
Peer Average Days Supply91
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 168.4% higher than the standard regional baseline profile for TN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13,591.23 across this reporting matrix range.

Provider Avg Cost Per Claim

$266.49

State Avg Cost Per Claim

$504.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Combination of imipenem and cilastatin that is used in the treatment of bacterial infections; cilastatin inhibits renal dehydropeptidase I to prolong the half-life and increase the tissue penetration of imipenem, enhancing its efficacy as an anti-bacterial agent.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections. This medication is known as a carbapenem-type antibiotic. It works by stopping the growth of bacteria.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like CATHERINE LE M.D. provides transparency into local medical care patterns within Nashville, TN.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Infectious Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.